natgillin/translations-raw huggingface dataset:
Gastrointestinal (GI) perforations and Fistulae (see section 4.4)
Seedetrakti perforatsioonid ja fistulid (vt lõik 4.4)
200 mg/m2 IV 2 h
Leukovoriin 200mg/m2i.v.
The safety and efficacy of bevacizumab, in addition to platinum-based chemotherapy, in the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC), was investigated in trials E4599 and BO17704.
Uuringutes E4599 ja BO17704 hinnati plaatinapreparaati sisaldavale keemiaravile lisatud bevatsizumabi ohutust ja efektiivsust mittelamerakulise mitteväikerakk-kopsuvähi esmavaliku ravina.
Asthenia, Fatigue, Pyrexia, Pain,
Asteenia, väsimus, palavik, valu, limaskestapõletik
Carboplatin/ Paclitaxel + bevacizumab 15 mg/kg q 3 weeks
1. päeval pluss bevatsizumabi 15 mg/kg i.v.
No clinically relevant interaction of co-administered chemotherapy on bevacizumab pharmacokinetics was observed based on the results of population pharmacokinetic analyses.
Populatsiooni farmakokineetiliste analüüside tulemuste põhjal ei täheldatud samaaegselt manustatud keemiaravi kliiniliselt olulist mõju bevatsizumabi farmakokineetikale.
Cases of foetal abnormalities in women treated with bevacizumab alone or in combination with known embryotoxic chemotherapeutics have been observed (see section 4.6) * If specified, the frequency has been derived from clinical trial data.
Loote väärarengute juhud naistel, kes said monoravi bevatsizumabiga või kombinatsioonis teadaolevalt embrüotoksiliste kemoterapeutikumidega (vt lõik 4.6).
Randomised patients with stage IV disease
Suboptimaalselt eemaldatud III staadiumi vähiga randomiseeritud patsiendid3
• Keep this leaflet.
• Toimeaine on bevatsizumab.
Progression-free survival Median time (months) Hazard ratio p-value
NPT suhtes tsenseeritud Mediaanne progressioonivaba elulemus (kuud) Riskitiheduste suhe (95% CI) p-väärtus
Oxaliplatin
RAVIMVORM
Posterior reversible encephalopath y syndromea,b,c, Hypertensive encephalopath yc
Renaalne trombootiline mikroangiopaatiab,c, aneurüsmid ja arteridissektsioonid
Gastro-intestinal disorders
Infusioonilahuse kontsentraat.
10x1 tablets
50 tabletti
These patients often do not have other treatment options.
Sageli puuduvad nendel patsientidel muud ravivõimalused.
Treatment is continued for 6 weeks, but may be extended for up to another 6 weeks if needed.
Ravi peab jätkama 6 nädalat, kuid seda võib vajaduse korral pikendada veel 6 nädalaks.
What measures are being taken to ensure the safe and effective use of Jorveza?
Mis meetmed võetakse, et tagada Jorveza ohutu ja efektiivne kasutamine?
Jorveza budesonide
Jorveza budesoniid
Other information about Jorveza
Muu teave Jorveza kohta
Tablets must not be chewed or swallowed whole.
Tablette ei tohi närida ega tervena alla neelata.
The European Medicines Agency decided that Jorveza's benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Jorveza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The tablet is placed on the tongue and pressed against the roof of the mouth for around two minutes until it dissolves.
Tablett pannakse keelele ja vajutatakse kuni lahustumiseni ehk ligikaudu kaheks minutiks suulakke.
After 6 weeks, around 58% of the patients taking Jorveza (34 out of 59 patients) had reduced eosinophils and no symptoms or only minimal symptoms, whereas none of the 29 patients taking placebo had these effects.
6 nädala pärast oli ligikaudu 58%-l (34 patsienti 59st) Jorvezat võtnud patsientidest eosinofiilide arv vähenenud ja sümptomid puudusid või esinesid ainult kerged sümptomid, samas kui seda toimet ei olnud mitte ühelgi 29-st platseebot kasutanud patsiendist.
What is Jorveza and what is it used for?
Mis on Jorveza ja milleks seda kasutatakse?
Why is Jorveza approved?
Miks Jorveza heaks kiideti?
Side effects with Jorveza are mainly the same as those of other similar medicines.
Jorveza kõrvaltoimed on valdavalt samasugused nagu teistel sarnastel ravimitel.
The summary of the opinion of the Committee for Orphan Medicinal Products for Jorveza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Jorveza kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
This is a summary of the European public assessment report (EPAR) for Jorveza.
See on ravimi Jorveza Euroopa avaliku hindamisaruande kokkuvõte.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Jorveza have been included in the summary of product characteristics and the package leaflet.
Jorveza ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
The full EPAR for Jorveza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Euroopa avaliku hindamisaruande täistekst Jorveza kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What are the risks associated with Jorveza?
Mis riskid Jorvezaga kaasnevad?
It is not intended to provide practical advice on how to use Jorveza.
Hindamisaruandes ei anta Jorveza kasutamise praktilisi nõuandeid.
During this time the patient should steadily swallow the saliva with the dissolved medicine.
Selle aja jooksul peab patsient suhu tekkiva sülje, millesse ravim on lahustunud, regulaarselt alla neelama.
Jorveza is available as orodispersible tablets (1 mg).
Jorvezat turustatakse suus dispergeeruvate tablettidena (1 mg).
The main measure of effectiveness was the level of eosinophils in the oesophagus and improvement in symptoms.
Efektiivsuse põhinäitja oli eosinfoiilide arv söögitorus ja sümptomite paranemine.
The most common side effects with Jorveza (which may affect up to 3 in 10 people) are fungal infections in the mouth, pharynx (throat) and oesophagus.
Jorveza kõige sagedamad kõrvalnähud (võivad esineda kuni 3 patsiendil 10st) on suu, neelu ja söögitoru seennakkused.
Corticosteroids help reduce inflammation by attaching to receptors of immune cells and reducing the release of substances that are involved in the inflammation process.
Kortikosteroidid (neerupealise koore hormoonid) aitavad vähendada põletikku, kinnitudes immuunrakkude retseptoritele ja vähendades põletikulises protsessis osalevate ainete vabanemist.
How does Jorveza work?
Kuidas Jorveza toimib?
Jorveza contains the active substance budesonide.
Jorveza sisaldab toimeainena budesoniidi.
For practical information about using Jorveza, patients should read the package leaflet or contact their doctor or pharmacist.
Kui vajate Jorveza kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
For the full list of all side effects and restrictions with Jorveza, see the package leaflet.
Jorveza kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
Because the number of patients with eosinophilic oesophagitis is low, the disease is considered ‘rare', and Jorveza was designated an ‘orphan medicine' (a medicine used in rare diseases) on 5 August
Et eosinofiilse ösofagiidiga patsientide arv on väike ja seda haigust esineb harva, nimetati Jorveza 5. augustil 2013 harvikravimiks.
For more information about treatment with Jorveza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate Jorvezaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
Jorveza benefits patients with eosinophilic oesophagitis by improving the symptoms of the disease and reducing the excess of eosinophils.
Jorveza parandab eosinofiilse ösofagiidiga patsientidel haiguse sümptomeid ja vähendab eosinofiilide liigset hulka.
Jorveza was compared with placebo (a dummy treatment).
Jorvezat võrreldi platseeboga (näiv ravim).
It is caused by a large build-up of white blood cells called eosinophils in the lining of the oesophagus.
Selle põhjuseks on teatud valgete vereliblede - eosinofiilide - ulatuslik kuhjumine söögitoru limaskestas.
What benefits of Jorveza have been shown in studies?
Milles seisneb uuringute põhjal Jorveza kasulikkus?
Jorveza is a medicine used to treat adults with eosinophilic oesophagitis.
Jorveza on ravim, mida kasutatakse eosinofiilse ösofagiidiga täiskasvanute raviks.
The active substance in Jorveza, budesonide, is a corticosteroid medicine.
Jorveza toimeaine budesoniid on kortikosteroidne ravim.
Eosinophilic oesophagitis is inflammation of the oesophagus (the food-pipe that leads from the mouth to the stomach), which causes symptoms including dysphagia (difficulty swallowing) and obstruction of the oesophagus.
Eosinofiilne ösofagiit on põletik söögitorus (suud maoga ühendav toru, mida mööda liigub toit), mis põhjustab muuhulgas selliseid sümptomeid, nagu düsfaagia (neelamisraskus) ja söögitoru ummistus.
After Jorveza dissolves in the mouth, the saliva carries it to the oesophagus where it reduces the inflammation and relieves the symptoms of eosinophilic oesophagitis.
Pärast Jorveza suus lahustumist kannab sülg ravimi söögitorru, kus see vähendab põletikku ja leevendab eosinofiilse ösofagiidi sümptomeid.
Jorveza was shown to be effective in one main study involving 88 adults with eosinophilic oesophagitis.
Ühes põhiuuringus, milles osales 88 eosinofiilse ösofagiidiga täiskasvanut, tõendati Jorveza efektiivsust.
How is Jorveza used?
Kuidas Jorvezat kasutatakse?
Jorveza can only be obtained with a prescription and treatment should be started by a doctor experienced with diagnosing and treating eosinophilic oesophagitis.
Ravi tohib alustada eosinofiilse ösofagiidi diagnoosimises ja ravimises kogenud arst.
Subcutaneous or intravenous use powder: multidose vial (glass); solvent: ampoule (glass)
Pulber ja lahusti süstelahuse valmistamiseks pulber: mitmeannuseline viaal (klaas); lahusti: ampull (klaas)
Solution 5000 IU/ml)
lahusti: 10 ml (valmislahus 5000 RÜ/ml)
H-1045 Budapest Hungary
H-1045 Budapest Ungari
Oficina D 28230 Las Rozas (Madrid) Spain
Oficina D 28230 Las Rozas (Madrid)
17 Bonifraterska Str. 00-203 Warsaw Poland
17 Bonifraterska Str. 00-203 Warsaw Poola
Ratiopharm - Comércio e Indústria de Produtos Farmacêuticos, Lda Lagos Park, Edíficio 5A, Piso 2
RatiopharmComércio e Indústria de Produtos Farmacêuticos, Lda Lagos Park, Edíficio 5A, Piso 2
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the Member States
I lisa Ravimite, ravimvormide, tugevuste, manustamisviiside, müügiloa hoidjate loetelu liikmesriikides
Generis Farmacêutica, S.A. Rua João de Deus, 19 Amadora
Rua João de Deus, 19 Amadora
104 25 Stockholm Sweden
104 25 Stockholm Rootsi
17674 Kallithea, Athens Greece
17674 Kallithea, Athens
Dunajska cesta 151 1000 Ljubljana Slovenia
Dunajska cesta 151 1000 Ljubljana Sloveenia
61118 Bad Vilbel
61118 Bad Vilbel Saksamaa
53757 Sankt Augustin Germany
53757 Sankt Augustin Saksamaa
DEMO ABEE 21st Km Athens-Lamias National Highway 14568 Kryoneri Greece
DEMO ABEE 21st Km AthensLamias National Highway 14568 Kryoneri Kreeka
LT-09310 Vilnius
LT-09310 Vilnius Leedu
40764 Langelfeld
40764 Langelfeld Saksamaa
86156 Augsburg
86156 Augsburg Saksamaa
EG LABO - Laboratoires EuroGenerics "Le Quintet" - bâtiment A 12, rue Danjou 92517 Boulogne Billancourt Cedex
EG LABOLaboratoires EuroGenerics "Le Quintet"bâtiment A 12, rue Danjou 92517 Boulogne Billancourt Cedex Prantsusmaa
Finland Sanofi Oy Huopalahdentie 24 PL 22
Sanofi Oy Huopalahdentie 24 PL 22
Sweden Sanofi AB Box 30052
Sanofi AB Box 30052
Via Scarlatti Domenico, 31 20124 Milano Italy
EG SpA Via Scarlatti Domenico, 31 20124 Milano Itaalia
02101 Espoo
02101 Espoo Soome
00350 Helsinki Finland
00350 Helsinki Soome
Germany Mylan dura GmbH Wittichstr.
Mylan dura GmbH Wittichstr.
1000 Ľubľana Slovenia
1000 Ľubľana Sloveenia
Winthrop Pharmaceuticals UK Limited
Ühendkuningriik Winthrop Pharmaceuticals UK Limited
Norton Healthcare Limited Ridings Point, Whistler Drive
Ridings Point, Whistler Drive
1080 Brussels
1080 Bruxelles Belgia
Germany Stadapharm GmbH Stadastr 2-18
Stadapharm GmbH Stadastr 2-18
Valproic acid Convulex gelule gastro résistante
Valproehape Convulex gelule gastro résistante
83607 Hozkirchen
25 83607 Hozkirchen Saksamaa
SI-1000 Ljubljana Slovenia
SI-1000 Ljubljana Sloveenia
89150 Laichingen
89150 Laichingen Saksamaa
Valproic acid Ácido Valpróico Generis
Valproehape Ácido Valpróico Generis
Centrafarm B.V. Nieuwe Donk 3 4879 AC ETTEN LEUR The Netherlands
Nieuwe Donk 3 4879 AC ETTEN LEUR Holland
85101 Bratislava Slovak Republic
Einsteinova 24 85101 Bratislava Slovakkia
Orlept (SF) Liquid or Sodium Valproate 40mg/ml oral solution
Orlept (SF) Liquid or Naatriumvalproaat 40mg/ml oral solution
Gastro-resistant capsule
Gastroresistentne kapsel
Sandoz B.V. Veluwezoom 22 1327 AH ALMERE The Netherlands
Veluwezoom 22 1327 AH ALMERE Holland
Remedica Ltd Aharnon Street Limassol Industrial Estate 3056 Lemesos Cyprus
Remedica Ltd Aharnon Street Limassol Industrial Estate
Desitin Arzneimittel Gmbh Weg beim Jaeger 214 DE-22335 Hamburg Germany
Weg beim Jaeger 214 DE-22335 Hamburg Saksamaa
Teva UK Limited Brampton Road, Hampden Park
Ühendkuningriik Teva UK Limited Brampton Road,
România
Rumeenia
63741 Aschaffenburg Germany
2a 63741 Aschaffenburg Saksamaa
Austria sanofi-aventis GmbH SATURN Tower, Vienna DC Leonard-Bernstein-Straße
Austria sanofi-aventis GmbH SATURN Tower, Vienna DC
90449 Nürnberg
Südwestpark 50 90449 Nürnberg Saksamaa
Romania GEROT PHARMAZEUTIKA Ges.m.b.H.
PHARMAZEUTIKA Ges.m.b.H.
Zentiva Italia Srl Viale Bodio 37/B 20158 Milano Italy
Zentiva Italia Srl Viale Bodio 37/B 20158 Milano Itaalia
Germany Hexal Aktiengesellschaft Industriestr.
Aktiengesellschaft Industriestr.
Luxembourg Hexal AG Industriestrasse 25 83067 Holzkirchen Germany
Industriestrasse 25 83067 Holzkirchen Saksamaa
103, Alexander Stamboliiski Blvd 1303 Sofia
Sanofi-Aventis Bulgaria EOOD 103, Alexander Stamboliiski Blvd 1303 Sofia Bulgaaria
Empreendimento Lagoas Park Edifício 7, 3º Piso, Porto Salvo
Empreendimento Lagoas Park Edifício 7, 3º Piso, Porto Salvo 2740-244 Porto Salvo Portugal
Largo Umberto Boccioni, 1 21040 Origgio (Varese) Italy
21040 Origgio (Varese) Itaalia
11317 Tallinn Estonia
Pärnu mnt 139E/2 11317 Tallinn Eesti
65926 Frankurt am main Germany
65926 Frankurt am main
Arrow Generiques 26, avenue Tony Garnier 69007 Lyon
Arrow Generiques 26, avenue Tony Garnier
Apotex Europe B.V. Darwinweg 20 2333 CR LEIDEN The Netherlands
Darwinweg 20 2333 CR LEIDEN Holland
Finland Orion Pharma Orionintie 1
Orion Pharma Orionintie 1 PL 65
Latvia sanofi-aventis Latvia SIA Kr.Valdemara 33-8 Riga LV1010
Kr.Valdemara 33-8 Riga LV1010
Luxembourg Takeda Belgium Chaussée de Gand 615 1080 Bruxelles
Takeda Belgium Gentsesteenweg 615 1080 Brussels Belgia
Belgium Mylan BVBA/SPRL Terhulpsesteenweg 6 box A 1560 Hoeilaart
Mylan BVBA/SPRL Terhulpsesteenweg 6 box A
Germany IIP - Institut für industrielle Pharmazie Forschungs- und Entwicklungsgesellschaft mbH
IIP - Institut für industrielle Pharmazie
LABORATOIRES ALTER 3, avenue de la Baltique, ZI de Courtaboeuf 91140 Villebon Sur Yvette France
ZI de Courtaboeuf 91140 Villebon Sur Yvette
ARENA GROUP S.A. Str. Ştefan Mihăileanu nr.
S.C. ARENA GROUP S.A.
Teva Nederland B.V. Swensweg 5 2031 GA HAARLEM The Netherlands
Swensweg 5 2031 GA HAARLEM Holland
Laboratoire AGUETTANT 1, rue Alexander Fleming 69007 Lyon
Laboratoire AGUETTANT 1, rue Alexander Fleming
Luxembourg Eurogenerics SA Esplanade Heysel b22
Eurogenerics SA Esplanade Heysel b22 1020 Bruxelles Belgia
Germany ALIUD PHARMA GmbH Gottlieb-Daimler-Str. 19
ALIUD PHARMA GmbH Gottlieb-Daimler-Str.
Sanofi-Aventis SpA Viale Luigi Bodio, 37/B 20158 Milano Italy
Sanofi-Aventis SpA Viale Luigi Bodio, 37/B 20158 Milano Itaalia
Sodium Valproate Tablets BP 500mg EC
Naatriumvalproaat Tablets BP 500mg EC
A-1160, Wien
Arnethgasse 3 A-1160, Wien Austria
Germany Ratiopharm GmbH Graf-Arco-Strasse 3
Ühendkuningriik Ratiopharm GmbH Graf-Arco-Strasse 3
Germany Heumann Pharma GmbH & Co. Generica KG Südwestpark 50
Heumann Pharma GmbH & Co. Generica KG
Sigma-Tau Industrie Farmaceutiche Riunite SpA Viale Shakespeare, 47 00144 Roma
Viale Shakespeare, 47 00144 Roma Itaalia
64295 Darmstadt Germany valprodura 150mg
64295 Darmstadt Saksamaa valprodura 150mg
Valproic acid VALPROATE SODIUM SANDOZ 500MG
Valproehape VALPROATE SODIUM SANDOZ 500MG
Generics UK Limited Station Close, Potter's Bar Hertfordshire EN6 1TL
Ühendkuningriik Generics UK Limited Station Close, Potter's Bar
64295 Darmstadt Germany valprodura 600 mg
64295 Darmstadt Saksamaa valprodura 600 mg
Gastroresistant tablets
Gastroresistentsed tabletid
Germany Winthrop Arzneimittel GmbH
Winthrop Arzneimittel GmbH
Ireland Sanofi-aventis Ireland Ltd. T/A SANOFI
Sanofi-aventis Ireland Ltd. T/A SANOFI Citywest Business Campus
64295 Darmstadt Germany valprodura 300 mg
64295 Darmstadt Saksamaa valprodura 300 mg
Valproic acid CONVULEX 100 mg/ml oldatos injekció
Valproehape CONVULEX 100 mg/ml oldatos injekció
Valproic acid ORFIRIL SAFT
Valproehape ORFIRIL SAFT
Valproic acid DEPAKINE 100 mg/ml por és oldószer oldatos injekcióhoz
Valproehape DEPAKINE 100 mg/ml por és oldószer oldatos injekcióhoz
Coated granules in sachet
Kaetud graanulid kotikeses
Valproic acid Diplexil
Valproehape Diplexil
Sanofi-Aventis France 1-13 Boulevard Romain Rolland
Sanofi-Aventis France 1-13 Boulevard Romain Rolland 75014 PARIS Prantsusmaa
Lithuania G.L.
Ühendkuningriik G.L.
500-1000 mg Modified-release granules
500-1000 mg Toimeainet modifitseeritult vabastavad graanulid
Powder for injection Intravenous use
Süstelahuse pulber Intravenoosne
Valpromide DEPAMIDE 300 mg, comprimé pelliculé gastro-résistant
Valpromiid DEPAMIDE 300 mg, comprimé pelliculé gastro-résistant
Kampenringweg 45 D-E 2803 PE GOUDA The Netherlands
2803 PE GOUDA Holland
Sodium valproate 100mg/ml solution for injection or infusion
Naatriumvalproaat 100mg/ml solution for injection or infusion
Valproic acid Convulex 50 mg/ml - Sirup für Kinder
Valproehape Convulex 50 mg/ml - Sirup für Kinder
Germany betapharm Arzneimittel GmbH
betapharm Arzneimittel GmbH
92931 Paris La Défense Cedex
TEVA SANTE 110, Esplanade du Général de Gaulle 92931 Paris La Défense Cedex Prantsusmaa
Belgium Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem
Sanofi Belgium Leonardo Da Vincilaan
Valproic acid CONVULEX 50 mg/ml szirup gyermekeknek
Valproehape CONVULEX 50 mg/ml szirup gyermekeknek
Germany Aristo Pharma GmbH Wallenroder Str. 8-10
Aristo Pharma GmbH Wallenroder Str. 8-10 13435 Berlin Saksamaa
Valproic acid Diplexil 1000
Valproehape Diplexil 1000
Valproic acid Depakine 400 mg/4 ml
Valproehape Depakine 400 mg/4 ml
Sodium Valproate Tablets 200mg
Naatriumvalproaat Tablets 200mg
PSC 170 00 Holesovice Czech Republic
Holesovice Tsehhi
Germany 1 A Pharma GmbH Keltenring 1 + 3
1 A Pharma GmbH Keltenring 1 + 3 82041 Oberhaching Saksamaa
Valproic acid Orfiril Long
Valproehape Orfiril Long
Valproic acid DEPAKINE 50 mg/ml szirup 50 mg/ml
Valproehape DEPAKINE 50 mg/ml szirup 50 mg/ml
Valproic acid Valproat "Sandoz"
Valproehape Valproat "Sandoz"
Valproic acid Depakine Chrono 500
Valproehape Depakine Chrono 500
Valproic acid Convulex 100 mg/mlInjektionslösung
Valproehape Convulex 100 mg/mlInjektionslösung
Valproic acid Diplexil 150
Valproehape Diplexil 150
31, Sector 2
Str. Ştefan Mihăileanu nr. 31, Sector 2
Finland Sandoz A/S C. F. Tietgens Boulevard 40 5220 ODENSE SØ Denmark
Sandoz A/S C. F. Tietgens Boulevard 40
Valproic acid Orfiril Retard
Valproehape Orfiril Retard
Valproic acid Convulex 300 mg - Kapseln 300 mg
Valproehape Convulex 300 mg - Kapseln 300 mg
13435 Berlin espa-valept 300 mg retard 199.8 mg, 87 mg
Aristo Pharma GmbH Wallenroder Str. 8-10 13435 Berlin Saksamaa espa-valept 300 mg retard 199.8 mg, 87 mg
Denmark Sandoz A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark
Sandoz A/S Edvard Thomsens Vej
2015 Strovolos Nicosia Cyprus
Charalambou Mouskou 14 Street 2015 Strovolos Nicosia
Valproic acid Depakine Chronosphere
Valproehape Depakine Chronosphere
Valproic acid ORFIRIL 600
Valproehape ORFIRIL 600
Avenida Professor Doutor Cavaco Silva, 10 E 2740-255 Porto Salvo Portugal
Avenida Professor Doutor Cavaco Silva, 10 E
Valproic acid Convulex 500 mg - Kapseln 500 mg
Valproehape Convulex 500 mg - Kapseln 500 mg
Sanofi-Aventis Cyprus Ltd Charalambou Mouskou 14 Street
Sanofi-Aventis Cyprus Ltd
DEPAKINE CHRONO (SPHERE) 1000 mg/sachet Coated granules in sachet
DEPAKINE CHRONO (SPHERE) 1000 mg/kotike Kaetud graanulid kotikeses
Valproic acid CONVULEX RETARD 500MG 500 mg
Valproehape CONVULEX RETARD 500MG 500 mg
Valproic acid CONVULEX RETARD 300MG 300 mg
Valproehape CONVULEX RETARD 300MG 300 mg
D-22311 HAMBURG Deutschland
Postfach 630164 D-22311 HAMBURG Saksamaa
Valproic acid ORFIRIL 150
Valproehape ORFIRIL 150
Valproic acid Absenor 300 mg tablety s predĺženým uvoľňovaním
Valproehape Absenor 300 mg tablety s predĺženým uvoľňovaním
Valproic acid Depakine chrono 300 mg tablete s podaljšanim sproščanjem
Valproehape Depakine chrono 300 mg tablete s podaljšanim sproščanjem
Valproic acid Depakine Chrono 300
Valproehape Depakine Chrono 300
Valproic acid Depakine chrono 500 mg tablete s podaljšanim sproščanjem
Valproehape Depakine chrono 500 mg tablete s podaljšanim sproščanjem
Valproic acid Convulex 150 mg - Kapseln 150 mg
Valproehape Convulex 150 mg - Kapseln 150 mg
Orlept 500mg gastro-resistant tablets
Orlept 500mg Gastroresistentne tabletts
Valproic acid Convulex Capsules 150mg 150 mg
Valproehape Convulex Capsules 150mg 150 mg
Valproic acid Diplexil 500
Valproehape Diplexil 500
Valproic acid Absenor 500 mg tablety s predĺženým uvoľňovaním
Valproehape Absenor 500 mg tablety s predĺženým uvoľňovaním
Orlept 200mg gastro-resistant tablets
Orlept 200mg Gastroresistentne tabletts
Magnesium Valproate
Magneesiumv alproaat
Valproic acid Convulex 150
Valproehape Convulex 150
Germany Dolorgiet GmbH & Co.KG Otto-von-Guericke-Str. 1
Dolorgiet GmbH & Co.KG
Valproic acid CONVULEX 300 mg gyomornedv-ellenálló lágy kapszula
Valproehape CONVULEX 300 mg gyomornedv-ellenálló lágy kapszula
Valproic acid Convulex 150 mg gastroresistant capsules, soft
Valproehape Convulex 150 mg gastroresistant capsules, soft
Valproic acid Convulex 300 mg gastroresistant capsules, soft
Valproehape Convulex 300 mg gastroresistant capsules, soft
Valproic acid CONVULEX 150 mg gyomornedv-ellenálló lágy kapszula
Valproehape CONVULEX 150 mg gyomornedv-ellenálló lágy kapszula
Valproic acid Ácido Valpróico Sandoz 500 mg Comprimidos de libertação prolongada
Valproehape Ácido Valpróico Sandoz 500 mg Comprimidos de libertação prolongada
Sodium valproate liquid 200mg/5ml
Naatriumvalproaat liquid 200mg/5ml
Valproic acid CONVULEX 300 MG/ML
Valproehape CONVULEX 300 MG/ML
Valproic acid CONVULEX 500 mg gyomornedv-ellenálló lágy kapszula
Valproehape CONVULEX 500 mg gyomornedv-ellenálló lágy kapszula
Valproic acid Ácido Valpróico Ratiopharm 300 mg Comprimidos de libertação prolongada
Valproehape Ácido Valpróico Ratiopharm 300 mg Comprimidos de libertação prolongada
Valproic acid ORFIRIL 300
Valproehape ORFIRIL 300
Belgium Takeda Belgium Gentsesteenweg 615
Takeda Belgium Chaussée de Gand
Wockhardt UK Limited Ash Road North Wrexham Industrial Estate Wrexham, LL13 9UF United Kingdom
Ühendkuningriik Wockhardt UK Limited Ash Road North
Valproic acid Convulex 500 mg gastroresistant capsules, soft
Valproehape Convulex 500 mg gastroresistant capsules, soft
Valproic acid Ácido Valpróico Sandoz 300 mg Comprimidos de libertação prolongada
Valproehape Ácido Valpróico Sandoz 300 mg Comprimidos de libertação prolongada
Valproic acid Convulex Capsules 300mg 500 mg
Valproehape Convulex Capsules 300mg 500 mg
Valproic acid Diplexil 300
Valproehape Diplexil 300
Valproic acid Ácido Valpróico Ratiopharm 500 mg Comprimidos de libertação prolongada
Valproehape Ácido Valpróico Ratiopharm 500 mg Comprimidos de libertação prolongada
Valproic acid Convulex Capsules 500mg 300 mg
Valproehape Convulex Capsules 500mg 300 mg
Valproic acid Convulex 300 mg kapsuly
Valproehape Convulex 300 mg kapsuly
Lithuania UAB „SANOFI-AVENTIS LIETUVA“
Läti sanofi-aventis Latvia SIA